Jessica Grossman, IgGenix CEO

IgGenix sprints to clin­ic with peanut al­ler­gy can­di­date and ad­di­tion­al $40M

A small, Eli Lil­ly-backed biotech has re­ceived $40 mil­lion on its way to the clin­ic with a self-ad­min­is­tered in­jec­tion for peanut al­ler­gies.

IgGenix un­veiled a Se­ries B round on Mon­day to sup­port what CEO Jes­si­ca Gross­man calls a “rev­o­lu­tion­ary” ap­proach to pre­vent­ing both food and non-food al­ler­gies, from dairy to dust to dogs.

When an al­ler­gic re­ac­tion oc­curs, the body pro­duces an el­e­vat­ed amount of al­ler­gen-spe­cif­ic an­ti­bod­ies called im­munoglob­u­lin E, or IgE, trig­ger­ing an al­ler­gic cas­cade that can cause symp­toms from itch­ing to ana­phy­lac­tic shock. IgGenix is look­ing to re-en­gi­neer IgE an­ti­bod­ies, trans­form­ing them in­to IgG an­ti­bod­ies de­signed to al­le­vi­ate the al­ler­gic cas­cade.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.